Safety	O
and	O
immunogenecity	B:C4054739
of	O
a	O
live	O
attenuated	O
Rift	O
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	O
)	O
in	O
camels	O
Rift	O
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	O
disease	I:C0042769
,	O
enzootic	O
and	O
endemic	O
in	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	O
health	O
.	O

Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	B:C0042211
Rift	O
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	O
)	O
in	O
camels	O
Rift	O
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	O
disease	I:C0042769
,	O
enzootic	O
and	O
endemic	O
in	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	O
health	O
.	O

Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	O
Rift	B:C1548485
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	O
)	O
in	O
camels	O
Rift	O
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	O
disease	I:C0042769
,	O
enzootic	O
and	O
endemic	O
in	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	O
health	O
.	O

Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	O
Rift	O
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	B:C1548485
)	O
in	O
camels	O
Rift	O
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	O
disease	I:C0042769
,	O
enzootic	O
and	O
endemic	O
in	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	O
health	O
.	O

Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	O
Rift	O
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	O
)	O
in	O
camels	B:C0006801
Rift	O
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	O
disease	I:C0042769
,	O
enzootic	O
and	O
endemic	O
in	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	O
health	O
.	O

Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	O
Rift	O
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	O
)	O
in	O
camels	O
Rift	B:C0035613
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	O
disease	I:C0042769
,	O
enzootic	O
and	O
endemic	O
in	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	O
health	O
.	O

Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	O
Rift	O
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	O
)	O
in	O
camels	O
Rift	O
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	B:C0042769
disease	I:C0042769
,	O
enzootic	O
and	O
endemic	O
in	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	O
health	O
.	O

Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	O
Rift	O
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	O
)	O
in	O
camels	O
Rift	O
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	O
disease	I:C0042769
,	O
enzootic	B:C0277551
and	O
endemic	O
in	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	O
health	O
.	O

Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	O
Rift	O
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	O
)	O
in	O
camels	O
Rift	O
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	O
disease	I:C0042769
,	O
enzootic	O
and	O
endemic	B:C0277550
in	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	O
health	O
.	O

Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	O
Rift	O
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	O
)	O
in	O
camels	O
Rift	O
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	O
disease	I:C0042769
,	O
enzootic	O
and	O
endemic	O
in	O
Africa	B:C0001737
and	O
the	O
Arabian	O
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	O
health	O
.	O

Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	O
Rift	O
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	O
)	O
in	O
camels	O
Rift	O
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	O
disease	I:C0042769
,	O
enzootic	O
and	O
endemic	O
in	O
Africa	O
and	O
the	O
Arabian	B:C0003671
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	O
health	O
.	O

Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	O
Rift	O
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	O
)	O
in	O
camels	O
Rift	O
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	O
disease	I:C0042769
,	O
enzootic	O
and	O
endemic	O
in	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	B:C0086418
and	O
animal	O
health	O
.	O

Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	O
Rift	O
Valley	I:C1548485
fever	I:C1548485
vaccine	I:C1548485
(	O
CL13T	O
)	O
in	O
camels	O
Rift	O
Valley	I:C0035613
fever	I:C0035613
is	O
an	O
emerging	O
zoonotic	O
viral	O
disease	I:C0042769
,	O
enzootic	O
and	O
endemic	O
in	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	I:C0003671
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	B:C0003062
health	O
.	O

The	O
disease	B:C0035613
is	O
most	O
severe	O
in	O
ruminants	O
causing	O
abortions	O
in	O
pregnant	O
animals	O
,	O
especially	O
sheep	O
animals	I:C0036945
and	O
high	O
mortality	O
in	O
young	O
populations	O
.	O

The	O
disease	O
is	O
most	O
severe	O
in	O
ruminants	B:C0035950
causing	O
abortions	O
in	O
pregnant	O
animals	O
,	O
especially	O
sheep	O
animals	I:C0036945
and	O
high	O
mortality	O
in	O
young	O
populations	O
.	O

The	O
disease	O
is	O
most	O
severe	O
in	O
ruminants	O
causing	O
abortions	B:C0149814
in	O
pregnant	O
animals	O
,	O
especially	O
sheep	O
animals	I:C0036945
and	O
high	O
mortality	O
in	O
young	O
populations	O
.	O

The	O
disease	O
is	O
most	O
severe	O
in	O
ruminants	O
causing	O
abortions	O
in	O
pregnant	B:C0032961
animals	O
,	O
especially	O
sheep	O
animals	I:C0036945
and	O
high	O
mortality	O
in	O
young	O
populations	O
.	O

The	O
disease	O
is	O
most	O
severe	O
in	O
ruminants	O
causing	O
abortions	O
in	O
pregnant	O
animals	B:C0003062
,	O
especially	O
sheep	O
animals	I:C0036945
and	O
high	O
mortality	O
in	O
young	O
populations	O
.	O

The	O
disease	O
is	O
most	O
severe	O
in	O
ruminants	O
causing	O
abortions	O
in	O
pregnant	O
animals	O
,	O
especially	O
sheep	B:C0036945
animals	I:C0036945
and	O
high	O
mortality	O
in	O
young	O
populations	O
.	O

The	O
disease	O
is	O
most	O
severe	O
in	O
ruminants	O
causing	O
abortions	O
in	O
pregnant	O
animals	O
,	O
especially	O
sheep	O
animals	I:C0036945
and	O
high	O
mortality	O
in	O
young	O
populations	B:C1257890
.	O

High	O
mortality	O
rates	O
and	O
severe	O
clinical	O
manifestation	O
have	O
also	O
been	O
reported	B:C0684224
among	O
camel	O
populations	O
in	O
Africa	O
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	O
available	O
live	O
vaccines	I:C0042211
against	O
RVF	O
have	O
been	O
tested	O
for	O
safety	O
and	O
efficacy	O
in	O
this	O
species	O
.	O

High	O
mortality	O
rates	O
and	O
severe	O
clinical	O
manifestation	O
have	O
also	O
been	O
reported	O
among	O
camel	B:C0006801
populations	O
in	O
Africa	O
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	O
available	O
live	O
vaccines	I:C0042211
against	O
RVF	O
have	O
been	O
tested	O
for	O
safety	O
and	O
efficacy	O
in	O
this	O
species	O
.	O

High	O
mortality	O
rates	O
and	O
severe	O
clinical	O
manifestation	O
have	O
also	O
been	O
reported	O
among	O
camel	O
populations	B:C1257890
in	O
Africa	O
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	O
available	O
live	O
vaccines	I:C0042211
against	O
RVF	O
have	O
been	O
tested	O
for	O
safety	O
and	O
efficacy	O
in	O
this	O
species	O
.	O

High	O
mortality	O
rates	O
and	O
severe	O
clinical	O
manifestation	O
have	O
also	O
been	O
reported	O
among	O
camel	O
populations	O
in	O
Africa	B:C0001737
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	O
available	O
live	O
vaccines	I:C0042211
against	O
RVF	O
have	O
been	O
tested	O
for	O
safety	O
and	O
efficacy	O
in	O
this	O
species	O
.	O

High	O
mortality	O
rates	O
and	O
severe	O
clinical	O
manifestation	O
have	O
also	O
been	O
reported	O
among	O
camel	O
populations	O
in	O
Africa	O
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	O
available	O
live	B:C0042211
vaccines	I:C0042211
against	O
RVF	O
have	O
been	O
tested	O
for	O
safety	O
and	O
efficacy	O
in	O
this	O
species	O
.	O

High	O
mortality	O
rates	O
and	O
severe	O
clinical	O
manifestation	O
have	O
also	O
been	O
reported	O
among	O
camel	O
populations	O
in	O
Africa	O
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	O
available	O
live	O
vaccines	I:C0042211
against	O
RVF	B:C0035613
have	O
been	O
tested	O
for	O
safety	O
and	O
efficacy	O
in	O
this	O
species	O
.	O

High	O
mortality	O
rates	O
and	O
severe	O
clinical	O
manifestation	O
have	O
also	O
been	O
reported	O
among	O
camel	O
populations	O
in	O
Africa	O
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	O
available	O
live	O
vaccines	I:C0042211
against	O
RVF	O
have	O
been	O
tested	O
for	O
safety	O
and	O
efficacy	O
in	O
this	O
species	B:C1705920
.	O

In	O
this	O
study	B:C2603343
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	O
antibody	I:C0475463
response	O
)	O
of	O
the	O
thermostable	O
live	I:C0042211
attenuated	I:C0042211
RVF	O
CL13T	I:C1548485
vaccine	I:C1548485
were	O
evaluated	O
in	O
camels	O
in	O
two	O
different	O
preliminary	O
experiments	O
involving	O
16	O
camels	O
,	O
(	O
that	O
12	O
camels	O
and	O
4	O
pregnant	O
camels	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	B:C0475463
antibody	I:C0475463
response	O
)	O
of	O
the	O
thermostable	O
live	I:C0042211
attenuated	I:C0042211
RVF	O
CL13T	I:C1548485
vaccine	I:C1548485
were	O
evaluated	O
in	O
camels	O
in	O
two	O
different	O
preliminary	O
experiments	O
involving	O
16	O
camels	O
,	O
(	O
that	O
12	O
camels	O
and	O
4	O
pregnant	O
camels	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	O
antibody	I:C0475463
response	O
)	O
of	O
the	O
thermostable	B:C0042211
live	I:C0042211
attenuated	I:C0042211
RVF	O
CL13T	I:C1548485
vaccine	I:C1548485
were	O
evaluated	O
in	O
camels	O
in	O
two	O
different	O
preliminary	O
experiments	O
involving	O
16	O
camels	O
,	O
(	O
that	O
12	O
camels	O
and	O
4	O
pregnant	O
camels	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	O
antibody	I:C0475463
response	O
)	O
of	O
the	O
thermostable	O
live	I:C0042211
attenuated	I:C0042211
RVF	B:C1548485
CL13T	I:C1548485
vaccine	I:C1548485
were	O
evaluated	O
in	O
camels	O
in	O
two	O
different	O
preliminary	O
experiments	O
involving	O
16	O
camels	O
,	O
(	O
that	O
12	O
camels	O
and	O
4	O
pregnant	O
camels	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	O
antibody	I:C0475463
response	O
)	O
of	O
the	O
thermostable	O
live	I:C0042211
attenuated	I:C0042211
RVF	O
CL13T	I:C1548485
vaccine	I:C1548485
were	O
evaluated	B:C0220825
in	O
camels	O
in	O
two	O
different	O
preliminary	O
experiments	O
involving	O
16	O
camels	O
,	O
(	O
that	O
12	O
camels	O
and	O
4	O
pregnant	O
camels	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	O
antibody	I:C0475463
response	O
)	O
of	O
the	O
thermostable	O
live	I:C0042211
attenuated	I:C0042211
RVF	O
CL13T	I:C1548485
vaccine	I:C1548485
were	O
evaluated	O
in	O
camels	B:C0006801
in	O
two	O
different	O
preliminary	O
experiments	O
involving	O
16	O
camels	O
,	O
(	O
that	O
12	O
camels	O
and	O
4	O
pregnant	O
camels	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	O
antibody	I:C0475463
response	O
)	O
of	O
the	O
thermostable	O
live	I:C0042211
attenuated	I:C0042211
RVF	O
CL13T	I:C1548485
vaccine	I:C1548485
were	O
evaluated	O
in	O
camels	O
in	O
two	O
different	O
preliminary	O
experiments	B:C0681814
involving	O
16	O
camels	O
,	O
(	O
that	O
12	O
camels	O
and	O
4	O
pregnant	O
camels	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	O
antibody	I:C0475463
response	O
)	O
of	O
the	O
thermostable	O
live	I:C0042211
attenuated	I:C0042211
RVF	O
CL13T	I:C1548485
vaccine	I:C1548485
were	O
evaluated	O
in	O
camels	O
in	O
two	O
different	O
preliminary	O
experiments	O
involving	O
16	O
camels	B:C0006801
,	O
(	O
that	O
12	O
camels	O
and	O
4	O
pregnant	O
camels	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	O
antibody	I:C0475463
response	O
)	O
of	O
the	O
thermostable	O
live	I:C0042211
attenuated	I:C0042211
RVF	O
CL13T	I:C1548485
vaccine	I:C1548485
were	O
evaluated	O
in	O
camels	O
in	O
two	O
different	O
preliminary	O
experiments	O
involving	O
16	O
camels	O
,	O
(	O
that	O
12	O
camels	B:C0006801
and	O
4	O
pregnant	O
camels	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	O
antibody	I:C0475463
response	O
)	O
of	O
the	O
thermostable	O
live	I:C0042211
attenuated	I:C0042211
RVF	O
CL13T	I:C1548485
vaccine	I:C1548485
were	O
evaluated	O
in	O
camels	O
in	O
two	O
different	O
preliminary	O
experiments	O
involving	O
16	O
camels	O
,	O
(	O
that	O
12	O
camels	O
and	O
4	O
pregnant	B:C0032961
camels	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	O
antibody	I:C0475463
response	O
)	O
of	O
the	O
thermostable	O
live	I:C0042211
attenuated	I:C0042211
RVF	O
CL13T	I:C1548485
vaccine	I:C1548485
were	O
evaluated	O
in	O
camels	O
in	O
two	O
different	O
preliminary	O
experiments	O
involving	O
16	O
camels	O
,	O
(	O
that	O
12	O
camels	O
and	O
4	O
pregnant	O
camels	B:C0006801
)	O
.	O

The	O
study	B:C2603343
revealed	O
that	O
the	O
CL13T	O
vaccine	I:C1548485
was	O
safe	O
to	O
use	O
in	O
camels	O
and	O
no	O
abortions	O
or	O
teratogenic	O
effects	I:C0232910
were	O
observed	O
.	O

The	O
study	O
revealed	O
that	O
the	O
CL13T	B:C1548485
vaccine	I:C1548485
was	O
safe	O
to	O
use	O
in	O
camels	O
and	O
no	O
abortions	O
or	O
teratogenic	O
effects	I:C0232910
were	O
observed	O
.	O

The	O
study	O
revealed	O
that	O
the	O
CL13T	O
vaccine	I:C1548485
was	O
safe	O
to	O
use	O
in	O
camels	B:C0006801
and	O
no	O
abortions	O
or	O
teratogenic	O
effects	I:C0232910
were	O
observed	O
.	O

The	O
study	O
revealed	O
that	O
the	O
CL13T	O
vaccine	I:C1548485
was	O
safe	O
to	O
use	O
in	O
camels	O
and	O
no	O
abortions	B:C0149814
or	O
teratogenic	O
effects	I:C0232910
were	O
observed	O
.	O

The	O
study	O
revealed	O
that	O
the	O
CL13T	O
vaccine	I:C1548485
was	O
safe	O
to	O
use	O
in	O
camels	O
and	O
no	O
abortions	O
or	O
teratogenic	B:C0232910
effects	I:C0232910
were	O
observed	O
.	O

The	O
single	O
dose	O
of	O
the	O
vaccine	B:C0042211
stimulated	O
a	O
strong	O
and	O
long	O
-	O
lasting	O
neutralizing	O
antibody	I:C0475463
response	O
for	O
up	O
to	O
12	O
months	O
.	O

The	O
single	O
dose	O
of	O
the	O
vaccine	O
stimulated	O
a	O
strong	O
and	O
long	O
-	O
lasting	O
neutralizing	B:C0475463
antibody	I:C0475463
response	O
for	O
up	O
to	O
12	O
months	O
.	O

The	O
presence	B:C0150312
of	O
neutralization	O
antibodies	I:C0475463
is	O
likely	O
to	O
correlate	O
with	O
protection	O
;	O
however	O
protection	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
challenge	O
experiments	O
using	O
the	O
virulent	O
RVF	O
virus	I:C0035614
.	O

The	O
presence	O
of	O
neutralization	B:C0475463
antibodies	I:C0475463
is	O
likely	O
to	O
correlate	O
with	O
protection	O
;	O
however	O
protection	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
challenge	O
experiments	O
using	O
the	O
virulent	O
RVF	O
virus	I:C0035614
.	O

The	O
presence	O
of	O
neutralization	O
antibodies	I:C0475463
is	O
likely	O
to	O
correlate	O
with	O
protection	O
;	O
however	O
protection	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
challenge	O
experiments	B:C0681814
using	O
the	O
virulent	O
RVF	O
virus	I:C0035614
.	O

The	O
presence	O
of	O
neutralization	O
antibodies	I:C0475463
is	O
likely	O
to	O
correlate	O
with	O
protection	O
;	O
however	O
protection	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
challenge	O
experiments	O
using	O
the	O
virulent	O
RVF	B:C0035614
virus	I:C0035614
.	O

